An Improved Formulation of Mebendazole and Drug Combination to Improve Anti-cancer Activity

Case ID:
C13270
Disclosure Date:
9/26/2014
Description:
UNMET NEED
Glioblastoma multiforme (GBM) is the most common and aggressive brain cancer, and despite treatment advances, patient prognosis remains poor.

TECHNICAL DESCRIPTION
JHU researchers demonstrated that a customized and particular formulation of mebendazole improves its pharmacokinetics and anticancer efficacy in preclinical testing for brain cancer.  The bioavailability of oral administered mebendazole is enhanced with the improved formulation in particular for intracranial tumors. They show that the anticancer efficacy of our formulation of mebendezole is superior to three different marketed drugs. They also show that combining improved mebendazole with a P-glycoprotein inhibitor further extended survival in preclinical models, and that p-glycoprotien inhibitor in combination with mebendazole is an effective anti-cancer combination.

MAJOR RESULTS
  • For the first time,  the inventors show that a pure polymorph C formulation of oral mebendazole that has been developed, has superior efficacy in preclinical models of cancer, and has favorable drug distribution for brain cancer.
  • This specifically formulated oral mebendazole is currently in phase I clinical trial for newly diagnosed high grade glioma for the first time.
  • In preclinical models of brain cancer we show that a P-glycoprotein inhibitor further improves survival.

ASSOCIATED PUBLICATIONS
Neuro Oncol. 2011 Sep;13(9):974-82.
Clin Cancer Res. 2015 Aug 1;21(15):3462-70.
 
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Mebendazole Polymorph For Treatment And Prevention Of Tumors PCT: Patent Cooperation Treaty European Patent Office 16747414.7   2/8/2016     Pending
MEBENDAZOLE POLYMORPH FOR TREATMENT AND PREVENTION OF TUMORS PCT: Patent Cooperation Treaty Israel 253854 253854 2/8/2016 6/26/2021 2/8/2036 Granted
An Improved Formulation of Mebendazole and Drug Combination to Improve Anti-cancer Activity PCT: Patent Cooperation Treaty China 2016800144274 ZL201680014427.4 2/8/2016 6/25/2021 2/8/2036 Granted
An Improved Formulation of Mebendazole and Drug Combination to Improve Anti-cancer Activity PCT: Patent Cooperation Treaty India 201717028684 352734 2/8/2016 12/1/2020 2/8/2036 Granted
Mebendazole Polymorph For Treatment And Prevention Of Tumors PCT: Patent Cooperation Treaty Japan 2017-541687 6796586 2/8/2016 11/18/2020 2/8/2036 Granted
MEBENDAZOLE POLYMORPH FOR TREATEMENT AND PREVENTION OF TUMORS PCT: Patent Cooperation Treaty United States 15/548,959 11,110,079 8/4/2017 9/7/2021 2/8/2036 Granted
MEBENDAZOLE POLYMORPH FOR TREATEMENT AND PREVENTION OF TUMORS CON: Continuation United States 17/402,131 8/13/2021     Pending
Inventors:
Category(s):
For Information, Contact:
Nakisha Holder
nickki@jhu.edu
410-614-0300
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum